Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD)

Aliment Pharmacol Ther. 2026 Sep 10. doi: 10.1111/apt.70970. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Upadacitinib is an oral selective JAK1 inhibitor approved for moderate-to-severe Crohn's disease (CD), but real-world prospective multicentre data in advanced therapy-experienced (AT-exper

B Brigida Barberio